Related Experiment Video
Updated: May 7, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
In silico oncology: exploiting clinical studies to clinically adapt and validate multiscale oncosimulators
Abstract:
This paper presents a brief outline of the notion and the system of oncosimulator in conjunction with a high level description of the basics of its core multiscale model simulating clinical tumor response to treatment. The exemplary case of lung cancer preoperatively treated with a combination of chemotherapeutic agents is considered. The core oncosimulator model is based on a primarily top-down, discrete entity - discrete event multiscale simulation approach. The critical process of clinical adaptation of the model by exploiting sets of multiscale data originating from clinical studies/trials is also outlined. Concrete clinical adaptation results are presented. The adaptation process also conveys important aspects of the planned clinical validation procedure since the same type of multiscale data - although not the same data itself- is to be used for clinical validation. By having exploited actual clinical data in conjunction with plausible literature-based values of certain model parameters, a realistic tumor dynamics behavior has been demonstrated. The latter supports the potential of the specific oncosimulator to serve as a personalized treatment optimizer following an eventually successful completion of the clinical adaptation and validation process.
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study

